Abstract
Gardenia jasminoides Ellis, a member of the Rubiaceae family, is a cornerstone of traditional Chinese medicine. While its general effects are well-documented, its specific anti-inflammatory role in mitigating intestinal mucosal injury induced by Lipopolysaccharides (LPS) has remained unclear. This study investigated the protective effects of a Gardenia jasminoides decoction (GD) on duodenal morphology and antioxidant capacity in an LPS-challenged mouse model. Chemical profiling via LC-ESI-QTOF-MS identified a complex array of active compounds. Results demonstrated that GD treatment significantly inhibited the production of pro-inflammatory cytokines (TNF-α, IL-6, IL-8, and IL-1) and attenuated histopathological damage in the duodenum. Furthermore, GD suppressed the expression of Nuclear factor-kappa B (NF-κB) and enhanced antioxidant enzyme activities (T-AOC, T-SOD, and GSH-Px). These findings suggest that Gardenia decoction is a potent therapeutic candidate for treating intestinal mucosal damage.
Introduction
The intestinal mucosa serves as a vital barrier, maintaining a delicate balance between nutrient absorption and protection against systemic pathogens. Disruptions to this barrier, often triggered by Lipopolysaccharides (LPS) from gram-negative bacteria, lead to a cascade of oxidative stress and a "cytokine storm," resulting in severe mucosal injury. Gardenia jasminoides (Zhi Zi) is traditionally used for its anti-inflammatory and cooling properties, but the molecular mechanisms underlying its efficacy in the gut required rigorous scientific validation.
Chemical Profiling and Identification
To understand the pharmacological basis of the decoction, researchers performed a comprehensive chemical characterization using High-Performance Liquid Chromatography coupled with Electrospray Ionization Quadrupole Time-of-Flight Mass Spectrometry (LC-ESI-QTOF-MS). This analysis, conducted in both positive and negative ion modes, identified dozens of bioactive compounds, including Geniposide, various flavonoids, and organic acids, which likely contribute to the decoction's multi-targeted therapeutic effects.
Experimental Methodology
The study utilized 50 male ICR mice divided into five experimental groups: a normal control, an LPS-injured model group, and three GD-treated groups receiving low, medium, and high doses. Following treatment, duodenal tissues were analyzed for morphological changes using Hematoxylin and Eosin (H&E) staining, focusing on villus height (VH) and crypt depth (CD). Serum cytokine levels were measured via ELISA, while the expression of NF-κB p65, a master regulator of inflammatory responses, was determined through Western blotting.
Key Results and Insights
1. Suppression of the Inflammatory Cascade
LPS administration typically triggers a massive release of pro-inflammatory cytokines. GD treatment demonstrated a significant, dose-dependent reduction in these markers. Notably, TNF-α levels in the high-dose GD group were nearly halved compared to the LPS-only model, effectively dampening the systemic inflammatory response.
2. Restoration of Antioxidant Defenses
Oxidative stress is a primary driver of mucosal degradation. The study found that GD upregulates the activities of endogenous antioxidant enzymes, including Total Antioxidant Capacity (T-AOC), Total Superoxide Dismutase (T-SOD), and Glutathione Peroxidase (GSH-Px). In the high-dose group, T-AOC and T-SOD levels were restored to states nearly identical to those of healthy controls, suggesting GD acts as a powerful scavenger of free radicals.
3. Preservation of Intestinal Architecture
LPS-induced injury typically results in fractured and shortened intestinal villi, which severely impairs nutrient absorption. GD treatment significantly preserved the structural integrity of the duodenum. The mucosal injury score, which peaked at 4.32 in the LPS group (indicating severe damage), was reduced to 1.23 in the high-dose GD group, reflecting only mild morphological changes.
4. Inhibition of the NF-κB Signaling Pathway
A critical finding of this research is the inhibition of the NF-κB p65 protein. By preventing the activation of this signaling pathway, GD stops the overproduction of inflammatory mediators at their source. Western blot analysis confirmed a clear reduction in NF-κB expression in mice treated with the decoction.
Discussion and Conclusion
This study provides robust evidence that Gardenia decoction protects the intestinal lining through a dual-action mechanism: suppressing the NF-κB-mediated inflammatory response and boosting the gut's internal antioxidant shield. While the synergy between specific compounds like Geniposide and flavonoids warrants further investigation, the dose-dependent efficacy observed here highlights GD as a promising therapeutic reagent for intestinal mucosal damage. Future research should explore the interaction between GD and the gut microbiome to further elucidate its role in maintaining intestinal homeostasis.
Summary updated